Quick Answer
Aclaris Therapeutics, Inc. reported Long Term Debt of $10.65 million for the year ending 2020.
- Aclaris Therapeutics, Inc. showed a decrease of -64.4% in Long Term Debt from 2018 to 2020.
- This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2022.
- XBRL data for this metric is available from 2018 to 2020 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $29.92 million | Q2 2019: $29.92 million | Q3 2019: $29.93 million | Q1 2020: $10.57 million | Q2 2020: $10.57 million | Q3 2020: $10.61 million | Q1 2021: $10.69 million | Q2 2021: $10.73 million.
- Historical annual values: Fiscal year 2020: $10.65 million | Fiscal year 2018: $29.91 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: